Tolterodine Extended Release With or Without Tamsulosin in Men With Lower Urinary Tract Symptoms Including Overactive Bladder Symptoms: Effects of Prostate Size

• Published in: European urology Vol. 55; no. 2; pp. 472 - 481
• Main Authors: Roehrborn, Claus G., Kaplan, Steven A., Jones, J. Stephen, Wang, Joseph T., Bavendam, Tamara, Guan, Zhonghong
• Format: Journal Article
• Language: English
• Published: Switzerland Elsevier B.V 01.02.2009
• Subjects: Adrenergic alpha-Antagonists - therapeutic use; Adult; Benign prostatic hyperplasia; Benzhydryl Compounds - administration & dosage; Benzhydryl Compounds - therapeutic use; Cresols - administration & dosage; Cresols - therapeutic use; Delayed-Action Preparations - administration & dosage; Delayed-Action Preparations - therapeutic use; Diuresis - drug effects; Drug Therapy, Combination; Humans; Lower urinary tract symptoms; Male; Middle Aged; Multicenter Studies as Topic; Muscarinic Agonists - administration & dosage; Muscarinic Agonists - therapeutic use; Organ Size; Overactive bladder; Phenylpropanolamine - administration & dosage; Phenylpropanolamine - therapeutic use; Prostate - anatomy & histology; Prostate - drug effects; Prostate volume; Quality of life; Randomized Controlled Trials as Topic; Sulfonamides - therapeutic use; Tamsulosin; Tolterodine extended release; Tolterodine Tartrate; Urinary Bladder, Overactive - drug therapy; Urinary Retention - epidemiology; Urology; Tamsulosin; Prostate volume; Benign prostatic hyperplasia; Overactive bladder; Tolterodine extended release; Lower urinary tract symptoms; Quality of life

Some men with lower urinary tract symptoms (LUTS) including overactive bladder (OAB) symptoms may benefit from antimuscarinic therapy, with or without an α-adrenergic antagonist. To evaluate the safety and efficacy of tolterodine extended release (ER), tamsulosin, or tolterodine ER+tamsulosin in men...